2024
Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart review
2023
Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Ren J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.Peer-Reviewed Original ResearchMeSH KeywordsCD4-Positive T-LymphocytesHumansLymphoma, T-Cell, CutaneousReceptors, Antigen, T-CellSkin NeoplasmsTranscriptomeConceptsCutaneous T-cell lymphomaMalignant CTCL cellsDiverse transcriptomic profilesT cellsSingle-cell RNACTCL cellsDevelopment of CTCLIntegrated transcriptomeT-cell receptor sequencingT cell exhaustion phenotypeCommon antigenic stimulusPeripheral blood CD4Transcriptomic profilesGene expressionT-cell lymphomaIntegrative analysisPotential therapeutic targetProliferation advantageLimited diversityBlood CD4Blood involvementMutation levelsExhaustion phenotypeWorse prognosisAntigenic stimulusProteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
Xu S, Ren J, Lewis J, Carlson K, Girardi M. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells. Journal Of Investigative Dermatology 2023, 143: 1322-1325.e3. PMID: 36642402, DOI: 10.1016/j.jid.2022.12.017.Peer-Reviewed Original Research
2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAdverse eventsHypericin-photodynamic therapyIndex lesionClinical trialsEarly-stage cutaneous T-cell lymphomaMycosis fungoides cutaneous T-cell lymphomaActive drugCommon treatment-related adverse eventsDrug-related serious adverse eventsResponse rateTreatment-related adverse eventsPhotodynamic therapyCutaneous T-cell lymphomaEnd pointLong-term adverse effectsLesion response ratePlaque-type lesionsPrimary end pointSecondary end pointsSerious adverse eventsWeeks of therapySignificant clinical responseApplication site reactionsWeeks of treatmentComment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”
Cohen JM, Damsky W, Girardi M. Comment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”. Journal Of The American Academy Of Dermatology 2022, 87: e241-e242. PMID: 35933070, DOI: 10.1016/j.jaad.2022.05.069.Peer-Reviewed Original ResearchPrimary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy designTreatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma
Cheraghlou S, Ugwu N, Girardi M. Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma. Journal Of The American Academy Of Dermatology 2022, 88: 203-205. PMID: 35476920, DOI: 10.1016/j.jaad.2022.04.032.Peer-Reviewed Original ResearchSentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
Cheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.Peer-Reviewed Original ResearchConceptsAcral lentiginous melanomaNational Cancer DatabaseClinical stage IBSLN positivityStage IBSentinel lymphCutaneous melanomaPositivity rateMalignant melanomaHigh riskSentinel lymph node statusAJCC Cancer Staging ManualClinical stage IRetrospective cohort studySignificant prognostic factorsLymph node statusCancer Staging ManualMultivariable logistic regressionHigher positivity rateAJCC clinical stageCohort studySLN statusPrognostic factorsSuch patientsStaging Manual
2021
Chronic UV radiation–induced RORγt+ IL-22–producing lymphoid cells are associated with mutant KC clonal expansion
Lewis JM, Monico PF, Mirza FN, Xu S, Yumeen S, Turban JL, Galan A, Girardi M. Chronic UV radiation–induced RORγt+ IL-22–producing lymphoid cells are associated with mutant KC clonal expansion. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2016963118. PMID: 34504008, PMCID: PMC8449378, DOI: 10.1073/pnas.2016963118.Peer-Reviewed Original ResearchConceptsChronic UV exposureLangerhans cellsIL-22Cutaneous carcinogenesisCutaneous squamous cell carcinoma (cSCC) developmentChronic ultraviolet radiation exposureSquamous cell carcinoma developmentClonal expansionEpidermal Langerhans cellsToll-like receptorsSkin cancer preventionGreatest risk factorDouble-deficient miceUltraviolet radiation exposureKey immune componentsImmune shiftKC growthIL-17ARisk factorsCancer preventionT cellsImmune responseCarcinoma developmentIntracellular CD3Immune componentsUncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings
King ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings. Journal Of Investigative Dermatology 2021, 142: 254-257. PMID: 34293349, DOI: 10.1016/j.jid.2021.04.035.Peer-Reviewed Original ResearchA machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis
Cheraghlou S, Sadda P, Agogo GO, Girardi M. A machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis. Australasian Journal Of Dermatology 2021, 62: 323-330. PMID: 34028790, DOI: 10.1111/ajd.13624.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMerkel cell carcinomaPositive lymph node countLymph node countPositive nodesDistant metastasisValidation cohortRare neuroendocrine skin cancerRetrospective cohort studyEnd Results registryLymph node biopsyLymph node metastasisThree-year survivalNeuroendocrine skin cancerNovel prognostic factorHigh mortality rateNode countAJCC groupsMCC stagingSEER cohortCohort studyMCC patientsNode biopsyPrognostic factorsNode metastasisAssociation of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma
Cheraghlou S, Christensen SR, Leffell DJ, Girardi M. Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma. JAMA Dermatology 2021, 157: 531-539. PMID: 33787836, PMCID: PMC8014201, DOI: 10.1001/jamadermatol.2021.0023.Peer-Reviewed Original ResearchConceptsMohs micrographic surgeryNational Cancer DatabaseTreatment facility characteristicsMicrographic surgeryInvasive melanomaCohort studyOverall survivalImproved long-term survivalLong-term patient survivalCox proportional hazards modelFacility characteristicsCancer-accredited facilitiesStudy of resectionRetrospective cohort studyMultivariable survival analysisWide local excisionHazard of deathTreatment of patientsLow-volume facilitiesProportional hazards modelEarly-stage melanomaFacility-level factorsLong-term survivalImproved survivalLocal excisionThe PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2021, 22: 407-414. PMID: 33656660, PMCID: PMC8068681, DOI: 10.1007/s40257-021-00591-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAgedAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleFemaleFollow-Up StudiesGelsHumansMaleMechlorethamineMiddle AgedMycosis FungoidesNeoplasm StagingProspective StudiesQuality of LifeSeverity of Illness IndexSkin NeoplasmsTreatment OutcomeUnited StatesConceptsHealth-related qualityMycosis fungoides cutaneous T-cell lymphomaCutaneous T-cell lymphomaChlormethine gelT-cell lymphomaMechlorethamine gelMonths post-treatment initiationEfficacy-evaluable patientsSkin-directed therapiesPrimary efficacy endpointProportion of patientsPatient-completed questionnairesPost-treatment initiationSkindex-29 scoresImportant therapeutic optionBody surface areaSkindex-29 questionnaireAssessment of responseReal-world studyPROVE StudyEfficacy endpointTopical corticosteroidsAdult patientsClinic visitsMycosis fungoidesNonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles
Hu JK, Suh HW, Qureshi M, Lewis JM, Yaqoob S, Moscato ZM, Griff S, Lee AK, Yin ES, Saltzman WM, Girardi M. Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2020575118. PMID: 33526595, PMCID: PMC7896333, DOI: 10.1073/pnas.2020575118.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaNonsurgical treatmentSkin cancerTumor cell surfaceIntratumoral drug deliveryHistologic cureCutaneous malignanciesSurgical excisionTherapeutic standardTumor burdenTumor immunotherapyTumor injectionCommon malignancyCell carcinomaSCC tumorsNonsurgical alternativeTherapeutic efficacyD postinjectionNanoparticle drug delivery systemsChemotherapeutic agentsSuperficial tumorsTumorsLocal deliveryEnhanced survivalPercutaneous delivery
2020
Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology
Yumeen S, Mirza FN, Lewis JM, Girardi M. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology. Journal Of Investigative Dermatology 2020, 140: 2319-2325.e1. PMID: 33222758, DOI: 10.1016/j.jid.2020.09.020.Peer-Reviewed Original ResearchConceptsCombination regimensCutaneous malignanciesMalignant cellsRelevant mouse modelPotential synergistic combinationsAdvanced cutaneous malignanciesClinical trial designChou-Talalay methodCancer cell linesClinical outcomesTherapy regimensDefinitive cureTargeted therapyTumor cell heterogeneityDrug combinationsMouse modelTrial designPreclinical developmentDrug resistanceRegimensCombination indexSynergistic activityOff-target effectsCritical pathwaysCell linesPrimary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementDisparities in outcomes of CD8+ cutaneous T‐cell lymphoma by race and presenting lesion location
Mirza F, Yumeen S, Girardi M. Disparities in outcomes of CD8+ cutaneous T‐cell lymphoma by race and presenting lesion location. British Journal Of Dermatology 2020, 184: 170-171. PMID: 32730673, DOI: 10.1111/bjd.19426.Peer-Reviewed Original ResearchClarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research—Reply
Cheraghlou S, Agogo GO, Girardi M. Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research—Reply. JAMA Dermatology 2020, 156: 1029-1029. PMID: 32520348, DOI: 10.1001/jamadermatol.2020.0543.Peer-Reviewed Original ResearchOutcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patientsScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original Research